Smith & Nephew SNATS Cash Flow from Operating Activities 2010-2024 | SNN
Smith & Nephew SNATS annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Smith & Nephew SNATS cash flow from operating activities for the quarter ending December 31, 2024 was $987M, a 376.81% increase year-over-year.
- Smith & Nephew SNATS cash flow from operating activities for the twelve months ending December 31, 2024 was $2.176B, a 8.65% decline year-over-year.
- Smith & Nephew SNATS annual cash flow from operating activities for 2024 was $0.987B, a 62.34% increase from 2023.
- Smith & Nephew SNATS annual cash flow from operating activities for 2023 was $0.608B, a 29.91% increase from 2022.
- Smith & Nephew SNATS annual cash flow from operating activities for 2022 was $0.468B, a 46.64% decline from 2021.
| Smith & Nephew SNATS Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $987 |
| 2023 | $608 |
| 2022 | $468 |
| 2021 | $877 |
| 2020 | $935 |
| 2019 | $1,168 |
| 2018 | $931 |
| 2017 | $1,090 |
| 2016 | $849 |
| 2015 | $1,030 |
| 2014 | $683 |
| 2013 | $867 |
| 2012 | $902 |
| 2011 | $842 |
| 2010 | $859 |
| 2009 | $719 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $12.535B | $5.810B |
| Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world | |||